信迪利单抗联合白蛋白结合型紫杉醇、奈达铂一线治疗食管癌的临床研究OA

Objective To investigate the clinical efficacy,safety,and changes in immunological indicators of sintilimab combined with albumin-bound paclitaxel and nedaplatin as first-line treatment for esophageal cancer.Methods A total of 100 patients with esophageal cancer admitted to Xuzhou First People's Hospital from May 2020 to December 2023 were selected and randomly divided into an observation group and a control group,with 50 cases in each group.The control group received treatment with albumin-bound paclitaxel and nedaplatin,while the observation group was treated with sintilimab combined with albumin-bound paclitaxel and nedaplatin.Before and after treatment,the therapeutic efficacy was assessed in two groups of patients.The tumor markers[cytokeratin 19 fragment antigen 21-1(CYFRA21-1),squamous cell carcinoma antigen(SCC-Ag),carcinoembryonic antigen(CEA)],immune function indicators,and serum levels of programmed death 1(PD-1)and programmed death ligand 1(PD-L1)were measured,and adverse reactions were documented.Results The disease control rate was higher in the observation group(P＜0.05).The differences in serum levels of CEA,CYFRA21-1,SCC-Ag,CD3+,CD4+,CD4+/CD8+,PD-1,and PD-L1 before and after treatment were greater in the observation group than in the control group(P＜0.05).There was no statistically significant difference in the overall incidence of adverse reactions between the two groups(P＞0.05).Conclusion Sintilimab combined with albumin-bound paclitaxel and nedaplatin demonstrates favorable efficacy in esophageal cancer,improves immune function,reduces tumor marker levels,and is associated with tolerable adverse effects,suggesting its potential for clinical application.